A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer
Kathrin Schwager1, Alessandra Villa, Christoph Rösli
1Philochem AG, ETH Zurich, Institute of Pharmaceutical Sciences, Zurich, Switzerland.
Background:
The antibody-based targeted delivery of bioactive molecules to tumour vasculature is an attractive avenue to concentrate therapeutic agents at cancer sites, while sparing normal organs. L19, F8 and F16 are three fully human monoclonal antibodies, specific to splice isoforms of fibronectin and tenascin-C, which bind to sites of active tissue remodeling and which are currently in Phase I and II clinical trials as radio-immunoconjugates and immunocytokines in patients with cancer and arthritis.In this article, we report the first comparative analysis of expression patterns for the extra domains EDB and EDA of fibronectin and A1 of tenascin-C in both primary and metastatic head and neck cancer lesions.
Methods:
We performed a comparative immunofluorescence analysis with the L19, F8 and F16 antibodies in 40 freshly frozen human head and neck cancer specimens.
Results:
On average, F8 and F16 exhibited similar staining intensities, which were typically stronger than L19. Interestingly, some specimens exhibited striking differences in staining by the three antibodies.
Conclusions:
These results suggests that an individualized treatment procedure (e.g., choice of L19, F8 or F16 based on immuno-PET or immunofluorescence procedure) may represent the most logical avenue for offering the best possible antibody to any given patient.
Insights
Antibody-based cancer therapy shows promise. Researchers compared three antibodies (L19, F8, F16) for targeting head and neck tumors, finding varied expression that could guide personalized treatment selection.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Antibody-based targeted delivery concentrates therapeutics at tumor sites, minimizing off-target effects.
- L19, F8, and F16 are fully human monoclonal antibodies targeting fibronectin and tenascin-C splice isoforms.
- These antibodies bind to sites of active tissue remodeling and are in clinical trials for cancer and arthritis.
Purpose of the Study:
- To conduct the first comparative analysis of EDB/EDA fibronectin and A1 tenascin-C expression in head and neck cancers.
- To evaluate the differential binding patterns of L19, F8, and F16 antibodies in these lesions.
Main Methods:
- Comparative immunofluorescence analysis was performed.
- The study utilized 40 freshly frozen human head and neck cancer specimens.
- L19, F8, and F16 antibodies were employed for staining.
Main Results:
- F8 and F16 antibodies generally showed stronger and similar staining intensities compared to L19.
- Significant variations in staining patterns were observed among the three antibodies across different specimens.
- Differential expression of fibronectin and tenascin-C isoforms was noted in primary and metastatic head and neck lesions.
Conclusions:
- Individualized antibody selection based on patient-specific expression patterns is crucial.
- Immuno-PET or immunofluorescence can guide the choice of L19, F8, or F16 for optimal patient outcomes.
- Personalized antibody selection represents a logical approach for maximizing therapeutic efficacy in head and neck cancer.
